HEcoPerMed published the 1st Newsletter

19. January 2021 – CSA HEcoPerMed stands for “Healthcare- and pharmaeconomics in support of the International Consortium for Personalised Medicine – ICPerMed”

In the recently published newsletter HEcoPerMed describes the three selected case studies on (1) MODY (Maturity Onset Diabetes of the Young), ToxNav, a test which is designed to personalised cancer treatment and a health economic model for the use of TRK inhibitors (NTRK). Another task is to develop guidance that can contribute to improved consistency and quality in economic evaluations of personalised medicine.

The Coordination and Support Action (CSA) HEcoPerMed is part of the so called ICPerMed family. The project goes beyond the current assessment and payment models in order to serve the need of personalised medicine (PM) for more comprehensive cost-effectiveness estimates – incorporating patient and societal perspectives – and for sustainable affordability of cutting-edge health innovations. One task of the CSA is to set up health economic guideline for PM approaches and another is the development of personalised medicine specific case studies.

More information:

1st Newsletter of the HEcoPerMed

About HEcoPerMed

The project flyer